Continue Reading
Full article on Yahoo Finance
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Market Intelligence Analysis
AI-Powered
Why This Matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term
Affected Symbols
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-25, effective May 4, 2026 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis
AI Breakdown
Summary
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Time Horizon
Short Term
Original article published by
Yahoo Finance
on April 30, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.